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Glimpse Into Multigene
are Variant Genetics
riple Mutations in
ypertrophic Cardiomyopathy*
ay E. Hershberger, MD
iami, Florida
our remarkable hypertrophic cardiomyopathy (HCM) pedi-
rees, each containing 1 individual harboring 3 HCM muta-
ions, have been published by Girolami et al. (1) in this issue of
he Journal. With a backdrop of the cardiovascular phenotypes
nd genotypes of their family members, these 4 individuals give
s a glimpse into the effects of multigene rare variant genetics.
he HCM genetic variants identified fit into a rare variant
aradigm (Table 1), and each met the usual criteria to be
onsidered a disease-causing mutation: the variant was found
n a known HCM gene, it was rare in the population, it
hanged a key amino acid, and in some cases it had been
eported previously in association with HCM. Variants in
ilated cardiomyopathy (DCM) and long QT syndrome also
ight be classified with a similar set of criteria (Table 1).
See page 1444
In patients with HCM, a putative disease-causing muta-
ion can be identified in 50% to 60% of patients, and of
hese, 80% to 85% of mutations—usually missense—are
ound in either MYH7, encoding beta myosin heavy chain,
r MYBPC3, encoding myosin binding protein C (2).
utations in TNNT2 or TNNI3, encoding cardiac troponin
or I, constitute another 10% of HCM mutations (2). An
ndividual harboring 2 mutations in HCM is not new and
as been reported in 2.5% (3), 3.5% (4), or 5% (5) of HCM
ases in association with earlier onset disease.
What added insights can be gained from these unusual
riple mutation HCM pedigrees? They strengthen the
oncept that multiple rare variants acting in concert actually
o modulate the HCM phenotype. They also show us that
he type of mutation (missense or nonsense), its relationship
o other mutations in the same gene (cis or trans), and the
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.a
From the Cardiovascular Division, Department of Medicine, University of Miami
iller School of Medicine, Miami, Florida.ombinations of different mutations (in the same or different
enes relevant for HCM) result in different phenotypes. In
ases 1 to 3, the individuals who carried 3 mutations had an
arlier onset (age 18, 29, and 24 years) and more aggressive
isease (heart failure, cardiac arrest, heart transplant, and so
orth), compared with their family members who carried 1
r 2 mutations or when compared with the remainder of the
84 probands. But 3 mutations did not always cause more
evere disease, because the individual in the fourth family
ith 3 mutations had an HCM phenotype with a 19-mm
eptum but was asymptomatic and otherwise normal. She
as a 48-year-old woman who underwent screening because
er brother, who carried 2 mutations, was diagnosed with
CM after presenting with minor symptoms. Her 3 daugh-
ers, all in their 30s, who carried combinations of 1 or 2 of
heir mother’s mutations, had normal cardiovascular screen-
ng. Notably, each of these mutations, 1 in MYH7 and the
ther 2 in MYBPC3, had been reported previously as
isease-causing when observed as solo mutations.
More generally, aside from multiple mutations in genes
nown to cause HCM, the variability of phenotypes be-
ween closely related family members carrying the same rare
ariant is commonly observed in genetic cardiomyopathy,
hether HCM or DCM (2). This phenotypic variability has
een attributed to environmental influences (e.g., blood
ressure, diet, activity) and the individual’s specific genetic
ackground, whether from common or rare variants. Efforts
ave been made to identify this genetic background in
nimal models and in humans (6). Although common
ariant genetics has received a great deal of attention,
rincipally to find risk factors for disease (Table 1) (7), the
agnitude of risk identified has been limited (8).
We all carry many variants that could cause or influence
enetic disease, but experimental issues have limited our
bilities to identify them. The sequencing of Craig Venter’s
eoxyribonucleic acid in 2007 with conventional capillary-
ased sequencing methods at great expense showed that he
arried an estimated 1.3 million novel variants, including
1,718 heterozygous and 9,434 homozygous coding vari-
nts; these were dispersed over 4,107 genes (9). A more
ecent and much less cost-intensive study, with exome
apture followed by massively parallel next-generation se-
uencing, gave similar results (10), where the exome is
efined as the 1% of the genome that encodes known
roteins. From 12 individuals of varied ethnicities, an
verage of 9,449 synonymous, 7,777 nonsynonymous, 46
onsense, 17 splice site variants, and 52 frameshift indels
ere identified/individual (10).
So what does the future hold? Exome sequencing, a major
echnological advance, will help to unravel the complexity of
are variant genetics. It is more tractable than current methods,
fficiently enriching exomic deoxyribonucleic acid, which is
hen applied to next-generation sequencing platforms that are
ore cost-effective than conventional methods. With this
pproach, variants can be identified in genes beyond the known
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April 6, 2010:1454–5 Rare Variant GeneticsCM genes that are relevant to HCM risk, causation,
resentation, or progression. Such new information will have
n enormous impact on the field. This is also likely to be the
ase for DCM genetics, on the basis of inferences from
reliminary studies (11,12), because rare variants in30 genes
ave been implicated in causing DCM, yet they explain no
ore than one-third of its genetic basis (2).
These are exciting times for cardiovascular rare variant
enetics—stay tuned!
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